ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2114

Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP

Jose Felix Restrepo1, Inmaculada del Rincon1, Roy W. Haas2, Daniel F. Battafarano3 and Agustin Escalante2, 1Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 3Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, joint destruction, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought to be involved in pathogenesis. Clinically, their presence identifies patients with more severe disease. Few studies have examined their combined effect on RA outcome. We studied a large cohort of RA patients focusing on the association of radiographic joint damage with the presence of the SE and anti-CCP. 

Methods:

A radiograph of both hands and wrists was used to measure erosions and joint-space narrowing in patients with RA, using the technique developed by Sharp et al. The SE was genotyped using sequence-specific primer amplification, and anti-CCP was measured using ELISA. An anti-CCP concentration of 20 IU or higher was considered positive. Patients were followed over time with repeated hand radiographs.  We used generalized estimating equations (GEE) with the Sharp score as a dependent variable to examine association between the SE and anti-CCP.  

Results:

We studied 1,328 RA patients. Of these, 1,264 (95%) had hand radiographs, as well as SE and anti-CCP results.  There were 3,824 radiographs, or 3.0 films per patient, over 8,700 patient-years of observation (6.9 years per patient).   The Sharp score at baseline was 47 (SD 61, range 0 to 294). The Sharp score progressed at a rate of 4.09 units per year (95% CI 3.96, 4.22) in the cohort considered as a whole.  Among the 157 patients who were negative for both the SE and anti-CCP, the Sharp score progressed at a rate of 2.76 units per year (2.44, 3.08). Among 449 patients who were positive for either the SE or the anti-CCP, the Sharp progression rate was 4.02 (3.82, 4.22, P < 0.001). Among 658 patients who were positive for both the SE and anti-CCP, Sharp progression rate was 4.50 (4.34, 4.67, P < 0.001).   We also examined at what point in time the mean Sharp score diverged significantly between the groups defined by SE and anti-CCP. Compared to patients who had negative SE and negative anti-CCP, patients who had positive SE and/or positive anti-CCP did not develop significantly higher Sharp score until 17 years of disease duration had passed. 

Conclusion:

Joint damage progressed more rapidly among RA patients who had positive SE and/or anti-CCP. However, it was not until well into the second decade of disease that the amount of damage in the patients with positive SE and/or positive anti-CCP became significantly different from those in whom these markers were negative.


Disclosure:

J. F. Restrepo,
None;

I. del Rincon,
None;

R. W. Haas,
None;

D. F. Battafarano,
None;

A. Escalante,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-damage-progression-in-rheumatoid-arthritis-role-of-the-hla-drb1-shared-epitope-and-anti-ccp/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology